Antibody Clinical Research Development DNA 
XTalks
DECEMBER 28, 2023
BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.
Find Me Cure
OCTOBER 13, 2019
If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 15, 2023
BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. Tumour-associated macrophages (TAMs) are an abundant immune cell population in many solid tumours and play a key role in establishing the immunosuppressive tumour microenvironment that enables tumour progression.
Drug Discovery World
OCTOBER 16, 2023
Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs.
Drug Discovery World
APRIL 11, 2024
On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development.
XTalks
FEBRUARY 13, 2023
Radiopharmaceutical therapy (RPT) uses isotopes that are conjugated to tumor-targeting agents (such as peptides, antibodies and novel small molecules). Radionuclide-ligand conjugates, including radionuclides that are conjugated to antibodies or peptides, have been studied extensively. How does Radiation Cause Cell Death?
Expert insights. Personalized for you.
97 
Let's personalize your content